| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 74 | 2024 | 4958 | 5.490 |
Why?
|
| Glioma | 35 | 2023 | 1978 | 4.270 |
Why?
|
| Laser Therapy | 13 | 2024 | 466 | 4.230 |
Why?
|
| Glioblastoma | 17 | 2021 | 1776 | 2.030 |
Why?
|
| Hyperthermia, Induced | 5 | 2021 | 511 | 1.790 |
Why?
|
| Magnetic Resonance Imaging | 46 | 2024 | 7895 | 1.770 |
Why?
|
| Craniotomy | 11 | 2021 | 304 | 1.740 |
Why?
|
| Monitoring, Intraoperative | 8 | 2017 | 264 | 1.610 |
Why?
|
| Brain Mapping | 16 | 2024 | 624 | 1.580 |
Why?
|
| Diffusion Tensor Imaging | 5 | 2022 | 293 | 1.360 |
Why?
|
| Wakefulness | 4 | 2014 | 156 | 1.240 |
Why?
|
| Neuronavigation | 6 | 2019 | 47 | 1.150 |
Why?
|
| Pyramidal Tracts | 3 | 2019 | 58 | 1.140 |
Why?
|
| Language | 6 | 2024 | 326 | 1.090 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 4 | 2021 | 33 | 1.010 |
Why?
|
| Motor Cortex | 6 | 2022 | 126 | 0.980 |
Why?
|
| Cortical Excitability | 1 | 2023 | 5 | 0.890 |
Why?
|
| Cerebral Cortex | 8 | 2019 | 623 | 0.780 |
Why?
|
| Butterflies | 1 | 2021 | 8 | 0.760 |
Why?
|
| Radiosurgery | 10 | 2024 | 1383 | 0.730 |
Why?
|
| Neurosurgical Procedures | 8 | 2020 | 633 | 0.720 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2019 | 50 | 0.670 |
Why?
|
| Infratentorial Neoplasms | 1 | 2019 | 48 | 0.660 |
Why?
|
| Adult | 65 | 2024 | 82040 | 0.610 |
Why?
|
| Brain | 14 | 2024 | 4208 | 0.590 |
Why?
|
| Radiation Injuries | 3 | 2020 | 1471 | 0.570 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2017 | 106 | 0.530 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2024 | 10400 | 0.530 |
Why?
|
| Middle Aged | 64 | 2024 | 90352 | 0.530 |
Why?
|
| Electric Stimulation | 7 | 2022 | 453 | 0.520 |
Why?
|
| Lasers | 3 | 2021 | 235 | 0.520 |
Why?
|
| Humans | 107 | 2024 | 270740 | 0.500 |
Why?
|
| Retrospective Studies | 31 | 2024 | 39890 | 0.480 |
Why?
|
| Deep Brain Stimulation | 1 | 2019 | 403 | 0.470 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 4 | 2017 | 339 | 0.470 |
Why?
|
| Aged | 51 | 2024 | 73333 | 0.460 |
Why?
|
| Male | 65 | 2024 | 128315 | 0.450 |
Why?
|
| Nervous System Diseases | 3 | 2013 | 517 | 0.430 |
Why?
|
| Evoked Potentials, Motor | 4 | 2023 | 60 | 0.420 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2014 | 261 | 0.410 |
Why?
|
| Intraoperative Complications | 1 | 2014 | 288 | 0.410 |
Why?
|
| Female | 71 | 2024 | 148940 | 0.400 |
Why?
|
| Young Adult | 24 | 2024 | 22251 | 0.350 |
Why?
|
| Meningeal Neoplasms | 4 | 2024 | 473 | 0.340 |
Why?
|
| Software | 3 | 2014 | 1355 | 0.340 |
Why?
|
| Cerebral Ventricle Neoplasms | 2 | 2023 | 76 | 0.330 |
Why?
|
| Gliosarcoma | 2 | 2012 | 32 | 0.330 |
Why?
|
| Necrosis | 3 | 2020 | 595 | 0.320 |
Why?
|
| Connectome | 2 | 2021 | 113 | 0.320 |
Why?
|
| Cerebral Veins | 2 | 2018 | 29 | 0.290 |
Why?
|
| Treatment Outcome | 19 | 2024 | 33737 | 0.260 |
Why?
|
| Postoperative Complications | 5 | 2019 | 5681 | 0.250 |
Why?
|
| Meningioma | 3 | 2024 | 308 | 0.250 |
Why?
|
| Glomus Jugulare Tumor | 1 | 2004 | 8 | 0.240 |
Why?
|
| Brachiocephalic Veins | 1 | 2004 | 20 | 0.240 |
Why?
|
| Ganglioneuroma | 1 | 2004 | 44 | 0.240 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2004 | 38 | 0.240 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2018 | 1690 | 0.240 |
Why?
|
| Cranial Sinuses | 1 | 2004 | 24 | 0.240 |
Why?
|
| Cerebellar Neoplasms | 2 | 2011 | 477 | 0.230 |
Why?
|
| Jugular Veins | 1 | 2004 | 113 | 0.230 |
Why?
|
| Neuroimaging | 3 | 2019 | 401 | 0.230 |
Why?
|
| Karnofsky Performance Status | 4 | 2020 | 174 | 0.230 |
Why?
|
| Prospective Studies | 10 | 2024 | 13414 | 0.230 |
Why?
|
| Glioma, Subependymal | 1 | 2023 | 24 | 0.220 |
Why?
|
| Adolescent | 17 | 2022 | 32767 | 0.220 |
Why?
|
| Speech | 2 | 2017 | 136 | 0.220 |
Why?
|
| Seizures | 2 | 2023 | 1001 | 0.220 |
Why?
|
| Growth Hormone | 1 | 2003 | 222 | 0.210 |
Why?
|
| Median Nerve | 1 | 2022 | 25 | 0.210 |
Why?
|
| Awards and Prizes | 1 | 2004 | 86 | 0.210 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2023 | 77 | 0.210 |
Why?
|
| Sensorimotor Cortex | 1 | 2022 | 22 | 0.200 |
Why?
|
| Follow-Up Studies | 7 | 2020 | 15218 | 0.200 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2022 | 51 | 0.200 |
Why?
|
| Isocitrate Dehydrogenase | 3 | 2020 | 522 | 0.200 |
Why?
|
| Pinealoma | 1 | 2022 | 50 | 0.200 |
Why?
|
| Skull Base | 1 | 2003 | 225 | 0.190 |
Why?
|
| Iatrogenic Disease | 1 | 2022 | 195 | 0.190 |
Why?
|
| Electrocorticography | 1 | 2022 | 79 | 0.190 |
Why?
|
| Pituitary Neoplasms | 1 | 2003 | 216 | 0.190 |
Why?
|
| Astrocytoma | 2 | 2014 | 326 | 0.190 |
Why?
|
| Brain Edema | 2 | 2019 | 95 | 0.190 |
Why?
|
| Tumor Burden | 5 | 2024 | 2033 | 0.190 |
Why?
|
| Preoperative Period | 3 | 2020 | 346 | 0.190 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2021 | 31 | 0.190 |
Why?
|
| Activating Transcription Factor 1 | 1 | 2020 | 21 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2019 | 6256 | 0.180 |
Why?
|
| Atlases as Topic | 2 | 2024 | 45 | 0.170 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 96 | 0.170 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2020 | 106 | 0.170 |
Why?
|
| Skull Base Neoplasms | 1 | 2004 | 339 | 0.170 |
Why?
|
| Myxoma | 1 | 2020 | 67 | 0.170 |
Why?
|
| Adenoviridae | 2 | 2018 | 1497 | 0.170 |
Why?
|
| Coloring Agents | 2 | 2004 | 233 | 0.160 |
Why?
|
| Preoperative Care | 4 | 2024 | 1567 | 0.160 |
Why?
|
| Adenoma | 1 | 2003 | 740 | 0.160 |
Why?
|
| Wernicke Area | 1 | 2017 | 11 | 0.150 |
Why?
|
| Surgical Oncology | 1 | 2020 | 211 | 0.150 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 557 | 0.150 |
Why?
|
| Combined Modality Therapy | 6 | 2020 | 9039 | 0.140 |
Why?
|
| Epilepsies, Partial | 1 | 2018 | 110 | 0.140 |
Why?
|
| Ki-67 Antigen | 1 | 2019 | 675 | 0.140 |
Why?
|
| Hand | 2 | 2021 | 175 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2004 | 801 | 0.140 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 336 | 0.130 |
Why?
|
| Melanoma | 5 | 2024 | 5595 | 0.130 |
Why?
|
| Oncolytic Viruses | 1 | 2018 | 169 | 0.130 |
Why?
|
| Ependymoma | 2 | 2003 | 264 | 0.130 |
Why?
|
| Thalamus | 1 | 2016 | 123 | 0.130 |
Why?
|
| Thionucleotides | 3 | 2001 | 66 | 0.130 |
Why?
|
| Oncolytic Virotherapy | 1 | 2018 | 239 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2017 | 293 | 0.120 |
Why?
|
| Cognition | 1 | 2021 | 959 | 0.120 |
Why?
|
| Prognosis | 8 | 2023 | 22505 | 0.120 |
Why?
|
| Immunotherapy | 3 | 2023 | 3557 | 0.120 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 30998 | 0.120 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2016 | 909 | 0.120 |
Why?
|
| Consensus | 1 | 2019 | 1106 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 1432 | 0.110 |
Why?
|
| Survival Rate | 7 | 2020 | 12541 | 0.110 |
Why?
|
| Robotic Surgical Procedures | 1 | 2020 | 533 | 0.110 |
Why?
|
| Ligamentum Flavum | 1 | 1993 | 2 | 0.110 |
Why?
|
| Epidural Neoplasms | 1 | 1993 | 8 | 0.110 |
Why?
|
| Carbon Monoxide | 1 | 1993 | 67 | 0.110 |
Why?
|
| Sarcoma | 1 | 2004 | 1839 | 0.110 |
Why?
|
| Skull Neoplasms | 1 | 1993 | 68 | 0.100 |
Why?
|
| Dacarbazine | 2 | 2012 | 502 | 0.100 |
Why?
|
| Phenytoin | 1 | 2013 | 81 | 0.100 |
Why?
|
| Neurologic Examination | 2 | 2009 | 262 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 625 | 0.100 |
Why?
|
| Survival Analysis | 4 | 2019 | 9292 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 700 | 0.100 |
Why?
|
| Ossification, Heterotopic | 1 | 1993 | 70 | 0.100 |
Why?
|
| Evoked Potentials, Somatosensory | 2 | 2022 | 67 | 0.100 |
Why?
|
| Cyclin B1 | 1 | 2011 | 60 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 4960 | 0.100 |
Why?
|
| Spinal Fusion | 2 | 2003 | 150 | 0.100 |
Why?
|
| Motor Skills Disorders | 1 | 2010 | 18 | 0.090 |
Why?
|
| G2 Phase | 1 | 2011 | 218 | 0.090 |
Why?
|
| Hydrocephalus | 1 | 1993 | 259 | 0.090 |
Why?
|
| Electrophysiological Phenomena | 1 | 2010 | 93 | 0.090 |
Why?
|
| Oligodendroglioma | 1 | 2010 | 105 | 0.090 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2011 | 210 | 0.090 |
Why?
|
| Nerve Fibers | 1 | 2010 | 119 | 0.090 |
Why?
|
| Brain Diseases | 2 | 2009 | 412 | 0.090 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 10265 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 537 | 0.080 |
Why?
|
| Anticonvulsants | 1 | 2013 | 430 | 0.080 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2012 | 605 | 0.080 |
Why?
|
| Anesthesia, General | 1 | 2010 | 222 | 0.080 |
Why?
|
| Neuroprotective Agents | 1 | 2011 | 220 | 0.080 |
Why?
|
| Perioperative Care | 1 | 2013 | 447 | 0.080 |
Why?
|
| Hydroxamic Acids | 1 | 2011 | 454 | 0.080 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2001 | 255 | 0.080 |
Why?
|
| Cytomegalovirus | 1 | 2011 | 496 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2019 | 585 | 0.070 |
Why?
|
| Neoplasm Grading | 3 | 2020 | 1823 | 0.070 |
Why?
|
| Monocytes | 1 | 2011 | 790 | 0.070 |
Why?
|
| Postoperative Period | 1 | 2009 | 666 | 0.070 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2011 | 617 | 0.070 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2007 | 160 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2009 | 714 | 0.070 |
Why?
|
| Animals | 9 | 2022 | 61956 | 0.070 |
Why?
|
| Genomics | 1 | 2017 | 2835 | 0.070 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2009 | 714 | 0.070 |
Why?
|
| Granular Cell Tumor | 1 | 2006 | 22 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 1312 | 0.070 |
Why?
|
| Lymphoma, B-Cell | 1 | 1993 | 929 | 0.070 |
Why?
|
| Quality of Life | 1 | 2020 | 4761 | 0.070 |
Why?
|
| Chemokines | 1 | 2007 | 290 | 0.070 |
Why?
|
| Proportional Hazards Models | 4 | 2023 | 5101 | 0.070 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1992 | 1067 | 0.060 |
Why?
|
| Logistic Models | 2 | 2010 | 3444 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2014 | 4831 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2009 | 2315 | 0.060 |
Why?
|
| Earache | 1 | 2004 | 8 | 0.060 |
Why?
|
| Sepharose | 1 | 2004 | 35 | 0.060 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2004 | 18 | 0.060 |
Why?
|
| Tinnitus | 1 | 2004 | 39 | 0.060 |
Why?
|
| Sella Turcica | 1 | 2003 | 23 | 0.060 |
Why?
|
| Sternum | 1 | 2004 | 96 | 0.060 |
Why?
|
| Orbital Neoplasms | 1 | 2006 | 234 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2000 | 840 | 0.060 |
Why?
|
| Fourth Ventricle | 1 | 2023 | 49 | 0.060 |
Why?
|
| Fusobacterium Infections | 1 | 2003 | 30 | 0.060 |
Why?
|
| Neoplasm Metastasis | 2 | 2014 | 5315 | 0.050 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2010 | 927 | 0.050 |
Why?
|
| Orthopedic Fixation Devices | 1 | 2002 | 19 | 0.050 |
Why?
|
| Spondylolisthesis | 1 | 2002 | 9 | 0.050 |
Why?
|
| Lumbosacral Region | 1 | 2003 | 55 | 0.050 |
Why?
|
| Pressure | 2 | 2004 | 178 | 0.050 |
Why?
|
| Fractures, Stress | 1 | 2002 | 11 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 1 | 2009 | 1136 | 0.050 |
Why?
|
| Brain Abscess | 1 | 2003 | 74 | 0.050 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2004 | 154 | 0.050 |
Why?
|
| Telomerase | 1 | 2006 | 547 | 0.050 |
Why?
|
| Interdisciplinary Communication | 1 | 2004 | 272 | 0.050 |
Why?
|
| ROC Curve | 2 | 2017 | 1248 | 0.050 |
Why?
|
| Consciousness | 1 | 2022 | 55 | 0.050 |
Why?
|
| Somatosensory Cortex | 1 | 2022 | 72 | 0.050 |
Why?
|
| Joint Instability | 1 | 2003 | 78 | 0.050 |
Why?
|
| Neurilemmoma | 1 | 2003 | 134 | 0.050 |
Why?
|
| Electrodes | 1 | 2022 | 132 | 0.050 |
Why?
|
| Computer Systems | 1 | 2022 | 113 | 0.050 |
Why?
|
| Sacrum | 1 | 2002 | 138 | 0.050 |
Why?
|
| Neurosurgery | 1 | 2003 | 117 | 0.050 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2003 | 303 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2004 | 4048 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2006 | 7783 | 0.050 |
Why?
|
| Unsupervised Machine Learning | 1 | 2021 | 20 | 0.050 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2020 | 21 | 0.050 |
Why?
|
| Cerebellum | 1 | 2004 | 470 | 0.050 |
Why?
|
| Cell Line, Tumor | 5 | 2020 | 14849 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2024 | 1430 | 0.050 |
Why?
|
| Gray Matter | 1 | 2021 | 60 | 0.040 |
Why?
|
| Apyrase | 1 | 2020 | 40 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2022 | 273 | 0.040 |
Why?
|
| 5'-Nucleotidase | 1 | 2020 | 63 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2004 | 661 | 0.040 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2000 | 44 | 0.040 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2020 | 49 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2022 | 7100 | 0.040 |
Why?
|
| Executive Function | 1 | 2021 | 146 | 0.040 |
Why?
|
| Apoptosis | 2 | 2011 | 7757 | 0.040 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 3035 | 0.040 |
Why?
|
| Models, Neurological | 1 | 2001 | 239 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 4328 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2004 | 823 | 0.040 |
Why?
|
| Biological Variation, Individual | 1 | 2018 | 3 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 1 | 2022 | 514 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2020 | 214 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 255 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2004 | 1330 | 0.040 |
Why?
|
| Hyperemia | 1 | 2018 | 36 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 4481 | 0.040 |
Why?
|
| Rats | 4 | 2001 | 6441 | 0.040 |
Why?
|
| Remission Induction | 1 | 2004 | 3656 | 0.040 |
Why?
|
| Periodicity | 1 | 2018 | 71 | 0.040 |
Why?
|
| Nerve Net | 1 | 2021 | 272 | 0.040 |
Why?
|
| Injections, Intralesional | 1 | 2018 | 169 | 0.040 |
Why?
|
| Publication Bias | 1 | 2017 | 37 | 0.040 |
Why?
|
| Spinal Neoplasms | 1 | 2003 | 670 | 0.040 |
Why?
|
| Memory | 1 | 2021 | 445 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2011 | 5759 | 0.040 |
Why?
|
| Electrodes, Implanted | 1 | 2018 | 185 | 0.040 |
Why?
|
| Blood-Brain Barrier | 1 | 1998 | 251 | 0.040 |
Why?
|
| Mutation | 2 | 2014 | 15912 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2017 | 274 | 0.030 |
Why?
|
| Child | 4 | 2018 | 30559 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 413 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 7914 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 659 | 0.030 |
Why?
|
| Machine Learning | 1 | 2019 | 360 | 0.030 |
Why?
|
| Biopsy | 2 | 2018 | 3484 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2020 | 1418 | 0.030 |
Why?
|
| Rats, Inbred F344 | 3 | 2001 | 239 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 514 | 0.030 |
Why?
|
| Anatomic Landmarks | 1 | 2015 | 51 | 0.030 |
Why?
|
| Metastasectomy | 1 | 2017 | 209 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2016 | 274 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 3409 | 0.030 |
Why?
|
| Anatomy, Artistic | 1 | 2014 | 9 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2018 | 17061 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 14012 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 1097 | 0.030 |
Why?
|
| Intracranial Aneurysm | 1 | 1995 | 130 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 1350 | 0.030 |
Why?
|
| Radiotherapy | 2 | 2011 | 1857 | 0.030 |
Why?
|
| Nerve Compression Syndromes | 1 | 1993 | 32 | 0.030 |
Why?
|
| Myelography | 1 | 1993 | 21 | 0.030 |
Why?
|
| Vertebral Artery | 1 | 1993 | 33 | 0.030 |
Why?
|
| Mice | 3 | 2022 | 35600 | 0.030 |
Why?
|
| Cell Division | 1 | 1997 | 2657 | 0.030 |
Why?
|
| Spinal Nerve Roots | 1 | 1993 | 69 | 0.030 |
Why?
|
| Globus Pallidus | 1 | 1993 | 67 | 0.030 |
Why?
|
| Parotid Neoplasms | 1 | 2014 | 150 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 1252 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2006 | 5002 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2011 | 3045 | 0.030 |
Why?
|
| Cerebral Ventricles | 1 | 1993 | 106 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2018 | 991 | 0.030 |
Why?
|
| Dura Mater | 1 | 1993 | 85 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 2025 | 0.030 |
Why?
|
| Drug Administration Routes | 2 | 2004 | 60 | 0.030 |
Why?
|
| Supratentorial Neoplasms | 1 | 2013 | 77 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 2211 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2020 | 5694 | 0.030 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2014 | 235 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 2271 | 0.020 |
Why?
|
| Antineoplastic Agents | 3 | 2011 | 14617 | 0.020 |
Why?
|
| Ataxia | 1 | 1993 | 182 | 0.020 |
Why?
|
| Spinal Cord Compression | 1 | 1993 | 167 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1610 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2012 | 159 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2011 | 229 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2003 | 6764 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2011 | 438 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2011 | 113 | 0.020 |
Why?
|
| HL-60 Cells | 1 | 2011 | 318 | 0.020 |
Why?
|
| Drainage | 1 | 1993 | 462 | 0.020 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2011 | 197 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 2012 | 322 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 442 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 1133 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2011 | 3584 | 0.020 |
Why?
|
| Acetylation | 1 | 2011 | 515 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2011 | 453 | 0.020 |
Why?
|
| Texas | 1 | 2020 | 6449 | 0.020 |
Why?
|
| Radiographic Image Enhancement | 1 | 1992 | 410 | 0.020 |
Why?
|
| Spinal Cord | 1 | 1993 | 718 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 5162 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2011 | 6390 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2011 | 451 | 0.020 |
Why?
|
| Contrast Media | 1 | 2015 | 1499 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2011 | 483 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2011 | 7238 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 2357 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2013 | 1060 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2011 | 701 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 1553 | 0.020 |
Why?
|
| Chemokine CCL22 | 1 | 2007 | 14 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 1145 | 0.020 |
Why?
|
| Receptors, CCR4 | 1 | 2007 | 35 | 0.020 |
Why?
|
| Receptors, CCR2 | 1 | 2007 | 44 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 2057 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 1199 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2011 | 672 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2011 | 967 | 0.020 |
Why?
|
| Carmustine | 1 | 2007 | 225 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 2011 | 495 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2009 | 593 | 0.020 |
Why?
|
| Zygoma | 1 | 2006 | 13 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2007 | 198 | 0.020 |
Why?
|
| Frontal Bone | 1 | 2006 | 28 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 6867 | 0.020 |
Why?
|
| Exophthalmos | 1 | 2006 | 46 | 0.020 |
Why?
|
| Cytoplasmic Granules | 1 | 2006 | 87 | 0.020 |
Why?
|
| Oculomotor Muscles | 1 | 2006 | 79 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2006 | 186 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2011 | 1857 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 2311 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 2580 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2007 | 702 | 0.020 |
Why?
|
| Bromphenol Blue | 1 | 2004 | 1 | 0.020 |
Why?
|
| Infusions, Intralesional | 1 | 2004 | 6 | 0.020 |
Why?
|
| Orbit | 1 | 2006 | 209 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 1051 | 0.010 |
Why?
|
| Gels | 1 | 2004 | 106 | 0.010 |
Why?
|
| Peptostreptococcus | 1 | 2003 | 7 | 0.010 |
Why?
|
| Bacteroides Infections | 1 | 2003 | 10 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2012 | 2123 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 1525 | 0.010 |
Why?
|
| Histones | 1 | 2011 | 1513 | 0.010 |
Why?
|
| Central Nervous System Diseases | 1 | 2004 | 134 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2011 | 4329 | 0.010 |
Why?
|
| Time Factors | 1 | 2017 | 13006 | 0.010 |
Why?
|
| Cell Movement | 1 | 2011 | 2472 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2011 | 1716 | 0.010 |
Why?
|
| Ilium | 1 | 2003 | 55 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2011 | 1456 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 3339 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 7655 | 0.010 |
Why?
|
| Incidence | 1 | 2013 | 5824 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 2115 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2014 | 2386 | 0.010 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2003 | 163 | 0.010 |
Why?
|
| Fluoroscopy | 1 | 2002 | 223 | 0.010 |
Why?
|
| Putamen | 1 | 2001 | 25 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 2002 | 247 | 0.010 |
Why?
|
| Diffusion | 1 | 2001 | 95 | 0.010 |
Why?
|
| Autoradiography | 1 | 2001 | 154 | 0.010 |
Why?
|
| Caudate Nucleus | 1 | 2001 | 42 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2014 | 2665 | 0.010 |
Why?
|
| Pelvis | 1 | 2003 | 381 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2014 | 3108 | 0.010 |
Why?
|
| Pregnancy | 1 | 2014 | 8130 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 16689 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2006 | 1712 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 2014 | 12033 | 0.010 |
Why?
|
| Swine | 1 | 2004 | 1607 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2011 | 9042 | 0.010 |
Why?
|
| Clostridium Infections | 1 | 2003 | 262 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 10708 | 0.010 |
Why?
|
| Phenotype | 1 | 2011 | 6509 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2001 | 927 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 16215 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2014 | 4895 | 0.010 |
Why?
|
| Genotype | 1 | 2006 | 4252 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2006 | 2166 | 0.010 |
Why?
|
| Drug Design | 1 | 2000 | 372 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1997 | 427 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 4147 | 0.010 |
Why?
|
| Aneurysm, Ruptured | 1 | 1995 | 44 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 5574 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 1995 | 148 | 0.010 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 1995 | 101 | 0.010 |
Why?
|
| Klippel-Feil Syndrome | 1 | 1993 | 11 | 0.010 |
Why?
|
| Infant | 1 | 2009 | 13999 | 0.010 |
Why?
|
| Dilatation, Pathologic | 1 | 1993 | 99 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 9470 | 0.010 |
Why?
|
| Reoperation | 1 | 1995 | 1392 | 0.010 |
Why?
|
| Algorithms | 1 | 2001 | 3891 | 0.010 |
Why?
|
| Radiography | 1 | 1993 | 1986 | 0.000 |
Why?
|
| Recurrence | 1 | 1995 | 4878 | 0.000 |
Why?
|